Page 31 - David Clair News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article MINNEAPOLIS, Feb. 11, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has recently published a paper entitled Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges (Yu, W et al.), in the highly rated peer-reviewed journal, Annals of Oncology (link). This review paper provides unique insight into liquid biopsies and the field of exosomes in the context of other liquid biopsies such as cfDNA and CTC analysis. The exosome field has gone through a rapid growth phase in ...

Share this article Share this article MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple Plex TM immunoassay cartridge portfolio to include nine new cartridge formats. These new cartridge offerings provide Simple Plex users with increased flexibility in the number of samples and biomarker assays run on each cartridge. Simple Plex assay cartridges, run on the Ella TM platform, utilizing state-of-the-art microfluidics to deliver a fully automated immunoassay solution. Researchers can cu...

Share this article Share this article MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2020. The quarterly dividend will be payable February 26, 2021 to all common shareholders of record on February 12, 2021. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clin...

Share this article Share this article MINNEAPOLIS, Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2020. Second Quarter FY2021 Snapshot Second quarter organic revenue increased by 19% (21% reported) to $224.3 million and 15% (16% reported) in the first half of fiscal 2021 to $428.5 million.   GAAP EPS was $1.15 versus $3.02 one year ago primarily relating to a non-recurring gain of approximately $121 million in our ChemoCentryx investment in the second quarter of fiscal 2020. Delivered record a...

Operator Good morning, and welcome to the Bio-Techne earnings conference call for the Second Quarter of Fiscal Year 2021. [Operator Instructions] I would now like to turn the call over to David Clair, Bio-Techne's Senior Director, Investor Relations and Corporate Development. David Clair -- Senior Director, Investor Relations & Corporate Development Good morning, and thank you for joining us. On the call with me this morning are Chuck Kummeth, Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne. Before we begin, let me briefly cover our safe harbor statement. Some ...